The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history of or risk factors for seizure were excluded. Men with mCRPC and seizure risk factors have an estimated seizure rate of 2.8 per 100 patient-years without enzalutamide exposure.
E nzalutamide, an androgen receptor inhibitor, has demonstrated efficacy in patients with metastatic castrationresistant prostate cancer (mCRPC).
1,2 A class effect of androgen receptor antagonists, 3 seizure is a known adverse effect of enzalutamide. [3] [4] [5] [6] In a phase 1 and 2 study, seizures were reported in 3 of 140 (2%) enzalutamide-treated patients at doses greater than 360 mg/d, with none reported at 160 mg/d, the approved clinical dose. 4 
Methods

Study Design
UPWARD was a prospective, global, multicenter, single-arm, open-label, postapproval safety study (ClinicalTrials.gov identifier: NCT01977651). There were 73 sites, in a total of 20 countries, including Argentina (6 sites), Australia (6 sites), Belgium (3 sites), Canada (4 sites), Chile (4 sites), Czech Republic (2 sites), Finland (3 sites), France (2 sites), Germany (3 sites), Hungary (1 site), Israel (8 sites), Italy (4 sites), New Zealand (1 site), Republic of Korea (5 sites), Singapore (1 site), Spain (6 sites), Sweden (2 sites), Taiwan (3 sites), the United Kingdom (1 site) and the United States (8 sites). Patients received oral enzalutamide, 160 mg/d, for an initial period of 4 months, with the option to continue treatment into a 1-year extension period. Inclusion and exclusion criteria are included in the eMethods in the Supplement. The data cutoff date for this study was February 1, 2016. The independent ethics committee or institutional review board reviewed the ethical, scientific, and medical appropriateness of the study before it was conducted. A list of the institutional review boards that approved the study is given in the eAppendix in the Supplement. Informed patient consent was obtained before study-related screening procedures were performed.
Primary and Secondary End Points
The primary end point was the percentage of evaluable patients with at least 1 independently confirmed seizure during the initial 4-month treatment period. Evaluable patients were defined as those who completed 3 months or more of treatment with enzalutamide or who had at least 1 confirmed seizure in the 4-month initial treatment period. Seizure evaluation methods and a list of medications that may lower seizure threshold are included in eTable 1 in the Supplement.
Secondary end points were the cumulative proportion of all patients with seizure events, including those occurring beyond the 4-month treatment period in the evaluable population, and the number of seizure events, including only the first seizure event, per patient-time exposure in the safety population (all patients who received ≥1 dose of enzalutamide). All subsequent seizure events were recorded. Adverse events were assessed in the safety population.
Statistical Analysis
Descriptive statistics were used for continuous variables (number of patients, mean, median, SD, minimum, and maximum). Frequencies (numbers) and percentages were displayed for categorical data. Percentages by category were based on the number of patients with complete data. The primary end point was estimated using the percentage point estimate and its 95% exact CI. Statistical significance was not calculated for the primary end point.
Key Points
Question Are seizure rates affected by treatment with enzalutamide in patients with metastatic castration-resistant prostate cancer who have seizure risk factors?
Finding In this open-label safety study of 423 patients receiving enzalutamide for metastatic castration-resistant prostate cancer, 4 patients experienced a confirmed seizure within the 4-month study period and 3 patients experienced a confirmed seizure following the 4-month study period. This incidence is similar to that in patients with metastatic castration-resistant prostate cancer and similar seizure risk factors but no enzalutamide exposure.
Meaning Enzalutamide did not increase seizure incidence in men with mCRPC and seizure risk factors.
Results
Patient Disposition, Demographics, and Baseline Characteristics
The study population consisted only of men owing to the nature of the disease. Overall, 531 patients were screened (mean age [SD] Figure) . A total of 101 (23.9%) patients discontinued treatment during the 4-month study treatment period. As of the data cutoff date of February 1, 2016, 220 (52.1%) patients were still receiving enzalutamide and 203 (47.9%) had discontinued treatment; of these, 111 (54.7%) discontinued because of progressive disease and 46 (23.2%) because of adverse events.
Baseline demographic and disease characteristics are shown in eTable 2 in the Supplement. The most common seizure risk factors at baseline are reported in eTable 3 in the Supplement. Of the 423 receiving enzalutamide, concomitant medications were taken by 417 patients (98.6%) during the study.
Among evaluable patients, 4 (1.1%; 95% CI, 0.3%-2.8%) had at least 1 confirmed seizure within 4 months of enzalutamide therapy initiation. Potentially relevant medical history, seizure risk factors, and seizure type are described in eTable 4 in the Supplement. Seizure events were considered enzalutamide-related in 3 of the 4 patients (eTable 4 in the Supplement).
An additional 3 patients had a seizure after 4 months of enzalutamide treatment (eTable 4 in the Supplement). Of the 7 patients who experienced a seizure, 3 continued treatment and all 3 had a second seizure. One patient with a second seizure had a history of seizure before study participation. Of the 3 patients with a second seizure, 1 was not given antiseizure medication after the first seizure and 2 received antiseizure medication (levetiracetam), of whom 1 received levetiracetam starting 2 days before the second seizure.
Incidence of confirmed seizure among the evaluable patients was 2.6 per 100 patient-years, based on a total exposure time of 272.25 patient-years and 7 patients with a confirmed seizure. After data cutoff, 1 additional patient experienced an independently confirmed seizure (convulsion).
Adverse Events
Overall, 423 patients were included in the safety analysis. Median duration of enzalutamide treatment was 223.0 days, with 322 patients (76.1%) receiving treatment for at least 4 months, 263 (62.2%) for at least 6 months, and 75 (17.7%) for more than 1 year.
Of the 423 patients, 357 (84.4%) reported at least 1 treatment-emergent adverse event, with 205 (48.5%) experiencing a drug-related (as assessed by the investigator) adverse event (Table) . The most frequently reported treatmentemergent adverse events are shown in the Table. Thirty-eight deaths (9.0%) occurred during treatment or within 30 days after treatment was discontinued; 4 deaths were considered drug related by the investigator (1 each of cerebral hemorrhage, mCRPC progression, sudden cardiac death, and general deterioration). No seizure-related deaths were reported.
Sixty-six patients (15.6%) permanently discontinued enzalutamide treatment because of a treatment-emergent adverse event; 3 of these discontinued because of a seizure event (convulsion, grand mal convulsion, and loss of consciousness).
Discussion
UPWARD, a postapproval safety study, investigated the incidence of independently confirmed seizure events in enzalutamide-treated men with mCRPC and at least 1 known risk factor for seizure at baseline. The incidence of seizures (2.6 per 100 patient-years) was comparable to that in a large retrospective analysis of patients in the United States with mCRPC and similar seizure risk factors but no exposure to enzalutamide (2.8 per 100 patient-years).
9
UPWARD results demonstrate that enzalutamide did not increase seizure incidence in men with mCRPC and predisposing factors. 
SAF indicates safety analysis set; SRES, seizure-risk evaluation set.
a Evaluable patients were defined as those who completed at least 3 months of treatment with enzalutamide or who had at least 1 confirmed seizure in the 4-month initial treatment period.
The safety profile of enzalutamide in UPWARD was generally consistent with that previously reported in enzalutamide-treated patients, including participants in large placebocontrolled phase 3 trials in mCRPC. As of data cutoff, 203 patients had withdrawn from the study; however, the number of withdrawals owing to disease progression and adverse events (37.4%) was lower than that observed for patients receiving enzalutamide in the AFFIRM (62.6%), PREVAIL (46.3%), and TERRAIN (48.6%) trials.
1,2,8
Limitations
There are limitations associated with this study; however, a randomized controlled trial was not deemed feasible. Although enrollment of patients with particular risk factors was monitored, enrollment within each category was not capped. Some preexisting seizure risk factors, including history of seizure and history of brain arteriovenous malformations, were underrepresented here but are higher than in the Truven report. 9 
Conclusions
Treatment with enzalutamide did not increase seizure incidence, which was within that expected for the population studied (ie, comparable to the incidence in patients with mCRPC and similar seizure risk factors without enzalutamide exposure). 9 Enzalutamide was generally well tolerated; adverse-event data were consistent with its known safety profile. 1, 2, 7, 8 These data suggest that enzalutamide did not increase seizure incidence in men with mCRPC and seizure risk factors and is an option for patients with seizure risk factors. However, it should be used with caution and input from neurology specialists. The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety. c All enrolled patients who took at least 1 dose of study drug and for whom any data were reported after the first dose of study drug (safety analysis set).
d Possible or probable, as assessed by the investigator, or records where relationship was missing.
e An adverse event was considered serious if, in the view of either the investigator or sponsor, it resulted in any of the following outcomes: resulted in death, was life-threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly or birth defect, required inpatient hospitalization or led to prolongation of hospitalization, or a medically important event.
4. Higano CS, Beer TM, Taplin ME, et al. Exclusion criteria included: history of exposure to enzalutamide; severe concurrent disease, infection, or comorbidity; current treatment with anti-seizure medication; history of seizure in the 12 months prior to screening; rapidly progressive visceral disease; clinical signs suggestive of high or imminent risks for pathologic fracture, spinal cord compression, and/or cauda equina syndrome; absolute neutrophil count <1500/ L; platelet count <100000/ L or hemoglobin <5.6 mmol/L (9 g/dL); total bilirubin levels ≥1.5 × upper limit of normal or alanine aminotransferase/aspartate aminotransferase levels ≥2.5 × upper limit of normal; estimated creatinine clearance of <30 mL/min; resting systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at screening; received an investigational agent within 4 weeks or five half-lives, whichever was longer, prior to day 1; and any condition that, in the investigator's opinion, made the patient unsuitable for study participation.
Evaluation of Suspected Seizures
The study site interviewed the patient and any witnesses, if possible, regarding the event and completed a Suspected Seizure Event Questionnaire. Suspected seizures were evaluated by a local neurologist using electroencephalograms and magnetic resonance imaging of the brain as soon as possible after the occurrence of the potential seizure event.
An Independent Adjudication Committee, consisting of three neurologists with expertise in epilepsy, was responsible for confirming all potential seizure events. For patients experiencing seizure events, an allowable antiepileptic could be administered on a maintenance basis and enzalutamide treatment continued at the discretion of the investigator. Prior chemotherapy 100 (23.6) a All enrolled patients who took ≥1 dose of study drug and for whom any data was reported after the first dose of study drug (safety analysis set). Race and/or ethnicity was documented as pre-specified in the protocol, in accordance with country-specific regulations. Abbreviations: ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.
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